Source: Healio News
The FDA granted orphan drug designation to LAVA-051 for the treatment of chronic lymphocytic leukemia.
LAVA-051 (Lava Therapeutics) is a bispecific antibody that activates the immune system to attack CD1d-expressing cancer cells.
Enrollment is underway for an open-label, multicenter phase 1/phase 2A trial designed to evaluate the agent for patients with relapsed or refractory CLL, multiple myeloma and acute myeloid leukemia.
Data from the phase 1 dose-escalation phase are expected in the first half of 2022. Topline clinical data from the phase 2A expansion cohorts are expected in the second half